These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 15927895)
1. Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein. Joy MS; Nickeleit V; Hogan SL; Thompson BD; Finn WF Pharmacotherapy; 2005 Jun; 25(6):779-89. PubMed ID: 15927895 [TBL] [Abstract][Full Text] [Related]
2. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium. Jacobson PA; Schladt D; Israni A; Oetting WS; Lin YC; Leduc R; Guan W; Lamba V; Matas AJ; Transplantation; 2012 Mar; 93(6):624-31. PubMed ID: 22334041 [TBL] [Abstract][Full Text] [Related]
3. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Kuypers DR; Naesens M; de Jonge H; Lerut E; Verbeke K; Vanrenterghem Y Ther Drug Monit; 2010 Aug; 32(4):394-404. PubMed ID: 20526235 [TBL] [Abstract][Full Text] [Related]
4. Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity. Haas M; Meehan SM; Josephson MA; Wit EJ; Woodle ES; Thistlethwaite JR Am J Kidney Dis; 1999 Jul; 34(1):69-84. PubMed ID: 10401019 [TBL] [Abstract][Full Text] [Related]
5. Different effect of cyclosporine and tacrolimus on renal expression of P-glycoprotein in human kidney transplantation. Yu X; Zhang B; Xing C; Sun B; Liu M; Zhang W; Gu M Transplant Proc; 2008 Dec; 40(10):3455-9. PubMed ID: 19100412 [TBL] [Abstract][Full Text] [Related]
6. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. Metalidis C; Lerut E; Naesens M; Kuypers DR Transplantation; 2011 May; 91(10):1098-102. PubMed ID: 21544031 [TBL] [Abstract][Full Text] [Related]
7. Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity. Yagisawa T; Omoto K; Shimizu T; Ishida H; Tanabe K Nephrology (Carlton); 2015 Jul; 20 Suppl 2():51-7. PubMed ID: 26031587 [TBL] [Abstract][Full Text] [Related]
8. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Tönshoff B; Höcker B Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497 [TBL] [Abstract][Full Text] [Related]
9. Calcineurin inhibitor nephrotoxicity. Naesens M; Kuypers DR; Sarwal M Clin J Am Soc Nephrol; 2009 Feb; 4(2):481-508. PubMed ID: 19218475 [TBL] [Abstract][Full Text] [Related]
10. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras. Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529 [TBL] [Abstract][Full Text] [Related]
11. Effect of calcineurin inhibitor therapy on P-gp expression and function in lymphocytes of renal transplant patients: a preliminary evaluation. Parasrampuria DA; Lantz MV; Birnbaum JL; Vincenti FG; Benet LZ J Clin Pharmacol; 2002 Mar; 42(3):304-11. PubMed ID: 11865967 [TBL] [Abstract][Full Text] [Related]
12. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Gruessner RW Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719 [TBL] [Abstract][Full Text] [Related]
13. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. Koziolek MJ; Riess R; Geiger H; Thévenod F; Hauser IA Kidney Int; 2001 Jul; 60(1):156-66. PubMed ID: 11422747 [TBL] [Abstract][Full Text] [Related]
14. Calcineurin inhibitor toxicity in renal allografts: morphologic clues from protocol biopsies. Sharma A; Jain S; Gupta R; Guleria S; Agarwal S; Dinda A Indian J Pathol Microbiol; 2010; 53(4):651-7. PubMed ID: 21045386 [TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. Joy MS; Hogan SL; Thompson BD; Finn WF; Nickeleit V Nephrol Dial Transplant; 2007 Jul; 22(7):1963-8. PubMed ID: 17395652 [TBL] [Abstract][Full Text] [Related]
17. Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Khanna A; Plummer M; Bromberek C; Bresnahan B; Hariharan S Kidney Int; 2002 Dec; 62(6):2257-63. PubMed ID: 12427154 [TBL] [Abstract][Full Text] [Related]
18. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Benigni A; Bruzzi I; Mister M; Azzollini N; Gaspari F; Perico N; Gotti E; Bertani T; Remuzzi G Kidney Int; 1999 Feb; 55(2):674-85. PubMed ID: 9987092 [TBL] [Abstract][Full Text] [Related]
19. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770 [TBL] [Abstract][Full Text] [Related]
20. Comparison of P-glycoprotein function in peripheral blood mononuclear cells ex vivo in stable Black and White male and female kidney transplant recipients. Tornatore KM; Attwood K; Brazeau D; Sprowl J; Chang S; Gundroo A; Minderman H; Venuto RC Clin Transl Sci; 2023 Feb; 16(2):184-192. PubMed ID: 36352830 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]